Clinically relevant RSV anti-F antibodies exhibit comparable inhibition of syncytium formation despite marked differences in neutralization potency
Journal of Virology · 06.11.2026
DOI: 10.1128/jvi.01155-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, online erschienen am 06.11.2026. Verfasst von Lotte T Azink und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in infants, immunocompromised individuals, and older adults. A hallmark of RSV infection is the formation of multinucleated syncytia through fusion between infected and adjacent uninfected cells. This process is mediated by the RSV fusion protein (RSV F) expressed on infected cells, which interacts with receptors on neighboring cells to drive membrane fusion. Syncytium formation may facilitate cell-to-cell spread while reducing virion exposure to extracellular neutralizing antibodies and immune cells. Clinically used monoclonal antibodies (mAbs) target RSV F and are routinely evaluated using conventional virus neutralization assays. However, their ability to inhibit syncytium formation remains poorly characterized because these assays primarily measure virus-to-cell entry rather than cell-to-cell fusion. Here, we present a quantitative flow cytometry-based assay to measure RSV-induced syncytium formation during infection. Using this assay, we evaluated clinically relevant anti-F mAbs and compared their potency in syncytium inhibition and conventional virus neutralization assays in HEp-2 and A549 cells. Palivizumab, nirsevimab, and clesrovimab inhibited syncytium formation in a dose-dependent manner, with only modest differences in potency. In contrast, nirsevimab and clesrovimab exhibited substantially greater virus neutralization potency than palivizumab. These findings indicate that inhibition of RSV-induced cell-to-cell fusion represents a distinct functional property of anti-F antibodies that is not fully captured by conventional neutralization assays. Our assay provides a quantitative approach to assess syncytium inhibition and highlights the value of complementary functional readouts for evaluating antibodies targeting RSV and other syncytium-forming viruses. IMPORTANCE Respiratory syncytial virus (RSV) is a leading cause of respiratory disease in infants, older adults, and immunocompromised individuals. A hallmark of RSV infection is syncytium formation, although its contribution to viral spread and disease pathogenesis remains incompletely understood. Increased fusogenicity has been associated with disease severity, and syncytium formation may promote cell-to-cell spread while limiting virion exposure to extracellular neutralizing antibodies. Although RSV fusion (F)-specific monoclonal antibodies (mAbs) are increasingly used for disease prevention, their ability to inhibit syncytium formation remains unexplored, as conventional neutralization assays primarily measure virus-to-cell entry. Here, we describe a quantitative flow cytometry-based assay to measure RSV-induced syncytium formation and evaluate inhibition by clinically relevant anti-F mAbs. Our results indicate that syncytium inhibition represents a distinct functional property of anti-F antibodies that is not fully captured by conventional neutralization assays, highlighting the value of complementary functional readouts for evaluating antibodies targeting RSV and other syncytium-forming viruses.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands.
ORCID-Profile: Lotte T Azink, Emmanuel J H J Wiertz, Robert Jan Lebbink
Zitieren
APA
Azink, L. T., Boonstoppel, T., Ramírez Alfaro, D., van Hal, C., Wiertz, E. J. H. J., & Lebbink, R. J. (2026). Clinically relevant RSV anti-F antibodies exhibit comparable inhibition of syncytium formation despite marked differences in neutralization potency. Journal of Virology. https://doi.org/10.1128/jvi.01155-26
Vancouver
Azink LT, Boonstoppel T, Ramírez Alfaro D, van Hal C, Wiertz EJHJ, Lebbink RJ. Clinically relevant RSV anti-F antibodies exhibit comparable inhibition of syncytium formation despite marked differences in neutralization potency. Journal of Virology. 2026. doi:10.1128/jvi.01155-26
BibTeX
@article{Azink2026,
author = {Azink, Lotte T and Boonstoppel, Thomas and Ramírez Alfaro, Daniel and van Hal, Claudia and Wiertz, Emmanuel J H J and Lebbink, Robert Jan},
title = {Clinically relevant RSV anti-F antibodies exhibit comparable inhibition of syncytium formation despite marked differences in neutralization potency},
journal = {Journal of Virology},
year = {2026},
doi = {10.1128/jvi.01155-26}
}
EUVIMED